PYC Therapeutics

12 November 2026

RESULTS OF 2026 ANNUAL GENERAL MEETING

PERTH, Australia and SAN FRANCISCO, California – 12 November 2026

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, PYC Therapeutics Limited (the 'Company') provides the following information in relation to the resolutions contained in the Notice of Meeting dated 12 October 2026 and considered at today's Annual General Meeting of Shareholders.

All resolutions were carried following a poll conducted at the meeting. The proxies received in respect of each resolution and the results of the poll are set out in the attached results summary.

This ASX announcement was approved and authorised for release by the Company Secretary of PYC Therapeutics Limited.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development[1].

For more information, visit pyctx.com, or follow us on LinkedIn.

CONTACT US

Investor relations and media contact
investor@pyctx.com

[1] Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank https://doi.org/10.1101/2020.11.02.20222232

Summary of Results

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 Remuneration Report	P	307,558,364 87.92%	42,208,095 12.07%	99,258	68,495 0.02%	320,148,720 88.35%	42,208,095 11.65%	99,258	-
2 Re-election of Peter Coleman as a Director of the Company	P	329,026,256 93.93%	21,213,953 6.06%	10,108	64,895 0.02%	342,023,922 94.16%	21,213,953 5.84%	115,928	Carried
3 Re-election of Professor Ian Constable AO as a Director	P	327,612,642 93.62%	22,248,967 6.36%	388,708	64,895 0.02%	340,716,128 93.87%	22,248,967 6.13%	388,708	Carried
4 Approval to issue options to Dr. Rohan Hockings	P	252,120,730 71.97%	98,111,139 28.01%	18,213	65,130 0.02%	264,813,541 72.97%	98,111,139 27.03%	18,213	Carried
5 Approval to issue Restricted Rights to Dr. Rohan Hockings	P	457,103,891 98.79%	5,540,249 1.20%	28,264	65,130 0.01%	469,796,702 98.83%	5,540,249 1.17%	28,264	Carried
6 Approval to issue Performance Rights to Dr. Rohan Hockings	P	461,904,145 99.82%	751,095 0.16%	17,164	65,130 0.01%	474,596,956 99.84%	751,095 0.16%	17,164	Carried
7 Approval to issue options to Professor Ian Constable AO	P	225,834,677 64.54%	124,003,486 35.44%	30,919	65,130 0.02%	238,938,398 65.83%	124,003,486 34.17%	30,919	Carried
8 Approval to grant rights to Professor Ian Constable AO	P	461,415,530 99.81%	832,400 0.18%	43,474	65,130 0.01%	474,413,431 99.82%	832,400 0.18%	43,474	Carried
9 Approval to grant rights to Peter Coleman	P	461,380,530 99.81%	832,400 0.18%	78,474	65,130 0.01%	474,378,431 99.82%	832,400 0.18%	78,474	Carried

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
10 Renewal of proportional takeover approval provisions	P	462,511,545 99.97%	58,804 0.01%	102,055	65,130 0.01%	475,615,266 99.99%	58,804 0.01%	102,055	Carried
11 Ratification of prior issue of Shares	P	72,631,942 99.88%	22,680 0.03%	26,276	65,130 0.09%	77,201,565 99.97%	22,680 0.03%	26,276	Carried